IBDEI0TD ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14500,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,14501,0)
 ;;=695.14^^90^860^59
 ;;^UTILITY(U,$J,358.3,14501,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14501,1,4,0)
 ;;=4^695.14
 ;;^UTILITY(U,$J,358.3,14501,1,5,0)
 ;;=5^SJS-TEN Syndrome
 ;;^UTILITY(U,$J,358.3,14501,2)
 ;;=^336637
 ;;^UTILITY(U,$J,358.3,14502,0)
 ;;=695.15^^90^860^71
 ;;^UTILITY(U,$J,358.3,14502,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14502,1,4,0)
 ;;=4^695.15
 ;;^UTILITY(U,$J,358.3,14502,1,5,0)
 ;;=5^Toxic Epidermal Necrolysis
 ;;^UTILITY(U,$J,358.3,14502,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,14503,0)
 ;;=695.19^^90^860^30
 ;;^UTILITY(U,$J,358.3,14503,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14503,1,4,0)
 ;;=4^695.19
 ;;^UTILITY(U,$J,358.3,14503,1,5,0)
 ;;=5^Erythema Multiforme NEC
 ;;^UTILITY(U,$J,358.3,14503,2)
 ;;=^336639
 ;;^UTILITY(U,$J,358.3,14504,0)
 ;;=V18.0^^90^861^15
 ;;^UTILITY(U,$J,358.3,14504,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14504,1,4,0)
 ;;=4^V18.0
 ;;^UTILITY(U,$J,358.3,14504,1,5,0)
 ;;=5^Family h/o Diabetes Mellitus
 ;;^UTILITY(U,$J,358.3,14504,2)
 ;;=^295311
 ;;^UTILITY(U,$J,358.3,14505,0)
 ;;=V16.0^^90^861^7
 ;;^UTILITY(U,$J,358.3,14505,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14505,1,4,0)
 ;;=4^V16.0
 ;;^UTILITY(U,$J,358.3,14505,1,5,0)
 ;;=5^Family h/o Cancer of GI Tract
 ;;^UTILITY(U,$J,358.3,14505,2)
 ;;=^295292
 ;;^UTILITY(U,$J,358.3,14506,0)
 ;;=V16.1^^90^861^8
 ;;^UTILITY(U,$J,358.3,14506,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14506,1,4,0)
 ;;=4^V16.1
 ;;^UTILITY(U,$J,358.3,14506,1,5,0)
 ;;=5^Family h/o Cancer of Lung
 ;;^UTILITY(U,$J,358.3,14506,2)
 ;;=^295293
 ;;^UTILITY(U,$J,358.3,14507,0)
 ;;=V19.6^^90^861^1
 ;;^UTILITY(U,$J,358.3,14507,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14507,1,4,0)
 ;;=4^V19.6
 ;;^UTILITY(U,$J,358.3,14507,1,5,0)
 ;;=5^Family h/o Allergic Disorder
 ;;^UTILITY(U,$J,358.3,14507,2)
 ;;=^295326
 ;;^UTILITY(U,$J,358.3,14508,0)
 ;;=V18.2^^90^861^2
 ;;^UTILITY(U,$J,358.3,14508,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14508,1,4,0)
 ;;=4^V18.2
 ;;^UTILITY(U,$J,358.3,14508,1,5,0)
 ;;=5^Family h/o Anemia
 ;;^UTILITY(U,$J,358.3,14508,2)
 ;;=^295313
 ;;^UTILITY(U,$J,358.3,14509,0)
 ;;=V17.5^^90^861^4
 ;;^UTILITY(U,$J,358.3,14509,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14509,1,4,0)
 ;;=4^V17.5
 ;;^UTILITY(U,$J,358.3,14509,1,5,0)
 ;;=5^Family h/o Asthma
 ;;^UTILITY(U,$J,358.3,14509,2)
 ;;=^295307
 ;;^UTILITY(U,$J,358.3,14510,0)
 ;;=V17.7^^90^861^3
 ;;^UTILITY(U,$J,358.3,14510,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14510,1,4,0)
 ;;=4^V17.7
 ;;^UTILITY(U,$J,358.3,14510,1,5,0)
 ;;=5^Family h/o Arthritis
 ;;^UTILITY(U,$J,358.3,14510,2)
 ;;=^295309
 ;;^UTILITY(U,$J,358.3,14511,0)
 ;;=V19.0^^90^861^5
 ;;^UTILITY(U,$J,358.3,14511,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14511,1,4,0)
 ;;=4^V19.0
 ;;^UTILITY(U,$J,358.3,14511,1,5,0)
 ;;=5^Family h/o Blindness
 ;;^UTILITY(U,$J,358.3,14511,2)
 ;;=^295320
 ;;^UTILITY(U,$J,358.3,14512,0)
 ;;=V16.3^^90^861^6
 ;;^UTILITY(U,$J,358.3,14512,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14512,1,4,0)
 ;;=4^V16.3
 ;;^UTILITY(U,$J,358.3,14512,1,5,0)
 ;;=5^Family h/o Cancer of Breast
 ;;^UTILITY(U,$J,358.3,14512,2)
 ;;=^295295
 ;;^UTILITY(U,$J,358.3,14513,0)
 ;;=V16.41^^90^861^9
 ;;^UTILITY(U,$J,358.3,14513,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14513,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,14513,1,5,0)
 ;;=5^Family h/o Cancer of Ovary
 ;;^UTILITY(U,$J,358.3,14513,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,14514,0)
 ;;=V16.42^^90^861^10
 ;;^UTILITY(U,$J,358.3,14514,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14514,1,4,0)
 ;;=4^V16.42
